X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Is Pancorona Virus Vaccine Possible? Dr. Weissman Says So

Content Team by Content Team
28th February 2022
in News
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

On the opening day of the 19th edition of BioAsia, a special fireside chat between Dr. Sangita Reddy, MD, of Apollo Hospitals and Dr. Drew Weissman, the pioneer who has brought mRNA tech to vaccines, spotlighted a revolutionary revelation about the future of coronavirus vaccination. Dr. Weismann spoke extensively about pancorona viruses, the state of healthcare costs, and the future of mRNA in therapeutics during a conversation with Dr. Sangita Reddy, MD, Apollo Hospitals. Dr. Weissman, a globally renowned researcher in mRNA technology for the rapid development of effective COVID-19 vaccines, discovered the modified nucleoside ability in RNA to quash the reactivity of innate immune sensors and boost the conversion of the nucleoside-modified mRNA in collaboration with Dr. Katalin Karikó. This groundbreaking discovery was used in the first two COVID-19 vaccines endorsed by Pfizer and Moderna, both of which used it.

The extraordinary efficacy of the modified RNA vaccines was a stunning result. Within 12 days of the second dose, infections were eradicated from the vaccinated individuals, with an efficacy rate of nearly 95%. According to Dr. Weissman, when mRNA is injected, it causes severe inflammation, killing the tissue. However, they developed a new type of RNA that is non-inflammatory, and this RNA is extremely effective and safe when used during inoculations. He adds that over a billion people have received RNA vaccines to date with almost no adverse events.

Because RNA is a complex molecule that is relatively easy to synthesise, it is a suitable and cost-effective technology to integrate into all other vaccine development efforts. Dr. Weissman is actively developing additional vaccines based on mRNA to induce sturdy antibody and T-cell responses. As far as the development of future vaccines is concerned, Dr. Weissman opines that they are working on a diverse array for a range of pathogens, such as HIV, HCV, HSV, malaria, influenza, and pancorona viruses. Additionally, he went on to say that they are developing vaccines against food allergies, cancer, immune disorders, therapeutic applications, and in vivo gene therapy.

Dr. Sangeeta Reddy discussed the impending next big scare – COVID’s third mutation, following Delta and Omicron. Dr. Weissman noted that coronavirus, like all other RNA viruses, is highly susceptible to mutation. He says that variants will continue to emerge as long as there is pervasive infection. He points out that only 15% of Africa has been inoculated, and immunisation of only a small percentage of the world’s population has taken place. Until the entire world is immunised, the virus will continue to mutate. That is what he believes in. Dr. Weissman observes that there are two options here; continue developing new vaccines whenever a new variant is discovered, and keep in mind that these variants only live for a short time in order to keep this cycle going.

Dr. Weismann confirms that they are developing a pancorona virus vaccine that will provide protection against all coronaviruses. There have been three coronavirus epidemics in the last two decades, and more are likely. As a result, they are working on developing a vaccine that will prevent any coronavirus from transmitting to humans. The vaccine, as per him, looks promising.

The future of mRNA technology is said to be extremely promising, with a plethora of applications. Additionally, it can be used therapeutically. Dr. Weissman and his lab personnel hope to develop mRNA therapy as a means of reducing inflammation in neurologic, stroke, and embolic events. His greatest hope is its usage in gene therapy, as someday, genetic diseases such as cystic fibrosis may be treatable.

Dr. Weissman also expressed optimism for India’s enhanced cooperation in the development of mRNA production sites. In his concluding remarks, he spoke out strongly against vaccine misinformation. He said that, on a systemic level, therapeutic equality is critical. With cost as the primary hindrance, government and privately funded research can contribute magnanimously to lowering costs and making it accessible to all.

Previous Post

WHO Puts In Place Another Training Hub For Biomanufacturing

Next Post

Strong Protection By New Sanofi Vaccine Against Severe COVID

Related Posts

Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Next Post
Strong Protection By New Sanofi Vaccine Against Severe COVID

Strong Protection By New Sanofi Vaccine Against Severe COVID

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In